Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study-Reference-Cited by-同舟云学术

Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Published:2022-11-16 Issue:1 Volume:25 Page:115-126
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Vázquez-Frias Rodrigo^ORCID,Consuelo-Sánchez Alejandra,Acosta-Rodríguez-Bueno Carlos Patricio,Blanco-Montero Andrés,Robles Daniel Casas,Cohen Vanessa,Márquez Daniel,Perez Marcos

Funder

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-022-00536-9.pdf

Reference67 articles.

1. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24(21):2211–35. https://doi.org/10.3748/wjg.v24.i21.2211.

2. Sun Y, Li L, Xie R, Wang B, Jiang K, Cao H. Stress triggers flare of inflammatory bowel disease in children and adults. Front Pediatr. 2019;7:432. https://doi.org/10.3389/fped.2019.00432.

3. Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471–8. https://doi.org/10.1016/j.cgh.2019.08.016.